Cargando…
Statins and immune checkpoint inhibitors: a strategy to improve the efficacy of immunotherapy for cancer?
In the past decade, immune checkpoint inhibitor (ICI) therapy significantly improved the prognosis of patients with cancer. Despite impressive and often unprecedented response rates, a significant portion of the patients fails to benefit from this treatment. Additional strategies to improve ICI effi...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9442479/ http://dx.doi.org/10.1136/jitc-2022-005611 |
_version_ | 1784782821471027200 |
---|---|
author | Vos, Winnie G Lutgens, Esther Seijkens, Tom T P |
author_facet | Vos, Winnie G Lutgens, Esther Seijkens, Tom T P |
author_sort | Vos, Winnie G |
collection | PubMed |
description | In the past decade, immune checkpoint inhibitor (ICI) therapy significantly improved the prognosis of patients with cancer. Despite impressive and often unprecedented response rates, a significant portion of the patients fails to benefit from this treatment. Additional strategies to improve ICI efficacy are therefore needed. The widespread clinical use of ICIs has increased our knowledge on the effects of the concomitant use of commonly prescribed drugs on the outcome of ICI treatment. A particular interesting class of drugs in this context are statins. These HMG-CoA reductase inhibitors, which are used to treat hypercholesterolemia and reduce the risk for atherosclerotic cardiovascular disease, are frequently used by patients with (advanced) cancer. This paper addresses the hypothesis that statins improve the efficacy of ICI therapy. |
format | Online Article Text |
id | pubmed-9442479 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-94424792022-09-14 Statins and immune checkpoint inhibitors: a strategy to improve the efficacy of immunotherapy for cancer? Vos, Winnie G Lutgens, Esther Seijkens, Tom T P J Immunother Cancer Hypothesis In the past decade, immune checkpoint inhibitor (ICI) therapy significantly improved the prognosis of patients with cancer. Despite impressive and often unprecedented response rates, a significant portion of the patients fails to benefit from this treatment. Additional strategies to improve ICI efficacy are therefore needed. The widespread clinical use of ICIs has increased our knowledge on the effects of the concomitant use of commonly prescribed drugs on the outcome of ICI treatment. A particular interesting class of drugs in this context are statins. These HMG-CoA reductase inhibitors, which are used to treat hypercholesterolemia and reduce the risk for atherosclerotic cardiovascular disease, are frequently used by patients with (advanced) cancer. This paper addresses the hypothesis that statins improve the efficacy of ICI therapy. BMJ Publishing Group 2022-09-02 /pmc/articles/PMC9442479/ http://dx.doi.org/10.1136/jitc-2022-005611 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Hypothesis Vos, Winnie G Lutgens, Esther Seijkens, Tom T P Statins and immune checkpoint inhibitors: a strategy to improve the efficacy of immunotherapy for cancer? |
title | Statins and immune checkpoint inhibitors: a strategy to improve the efficacy of immunotherapy for cancer? |
title_full | Statins and immune checkpoint inhibitors: a strategy to improve the efficacy of immunotherapy for cancer? |
title_fullStr | Statins and immune checkpoint inhibitors: a strategy to improve the efficacy of immunotherapy for cancer? |
title_full_unstemmed | Statins and immune checkpoint inhibitors: a strategy to improve the efficacy of immunotherapy for cancer? |
title_short | Statins and immune checkpoint inhibitors: a strategy to improve the efficacy of immunotherapy for cancer? |
title_sort | statins and immune checkpoint inhibitors: a strategy to improve the efficacy of immunotherapy for cancer? |
topic | Hypothesis |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9442479/ http://dx.doi.org/10.1136/jitc-2022-005611 |
work_keys_str_mv | AT voswinnieg statinsandimmunecheckpointinhibitorsastrategytoimprovetheefficacyofimmunotherapyforcancer AT lutgensesther statinsandimmunecheckpointinhibitorsastrategytoimprovetheefficacyofimmunotherapyforcancer AT seijkenstomtp statinsandimmunecheckpointinhibitorsastrategytoimprovetheefficacyofimmunotherapyforcancer |